Skip to main content
. Author manuscript; available in PMC: 2014 Jun 14.
Published in final edited form as: J Immunol. 2013 Oct 7;191(10):5124–5138. doi: 10.4049/jimmunol.1301415

Table I.

Potential HLA-A*0201–restricted epitopes selected from HSV gB

Peptide Sequence Molecular Mass (kDa) Amino Acids (No.) BIMAS SYFPEITHI MAPPP MHCPred
gB17–25 ALLGLTLGV 856.0 9 257.342 31 0.5241 0.27
gB161–169 TMYYKDVTV 1119.3 9 160.742 23 0.8421 0.34
gB183–191 GIFEDRAPV 1003.1 9 145.077 24 0.5003 0.24
gB286–294 FVLATGDFV 968.1 9 279.149 17 0.09
gB342–350 NLLTTPKFT 1034.2 9 151.648 15
gB343–351 LLTTPKFTV 1019.2 9 685.783 24 1 0.19
gB441–449 YLANGGFLI 967.1 9 278.347 24 0.2
gB447–455 FLIAYQPLL 1077.3 9 98.267 25 0.8300 0.4
gB561–569 RMLGDVMAV 991.2 9 427.474 27 0.7222 0.37
gB675–683 TMLEDHEFV 1120.2 9 2053.642 22 0.9942 0.19

The sequence of HSV-1 glycoprotein B was submitted to screening of potential HLA-A*0201 epitopes using several computer algorithms. Ten peptides were selected on the basis of HLA-A*0201 binding motif sequence from HSV-1 gB. The numbers in the four right columns show predicted IC50 as calculated by BIMAS (http://www-bimas.cit.nih.gov/molbio/hla_bind), SYFPEITHI http://www.syfpeithi.de), MAPPP (http://www.mpiib-berlin.mpg.de/MAPPP), and MHCPred (http://www.mhc-pathway.net). The sequences of synthesized peptides are based on the HSV-1 strain 17.